中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Issue 11
Nov.  2018
Turn off MathJax
Article Contents

Experience in diagnosis and treatment of acute graft-versus-host disease after liver transplantation of 8 cases

DOI: 10.3969/j.issn.1001-5256.2018.11.025
  • Published Date: 2018-11-20
  • Objective To investigate the diagnosis and treatment of acute graft-versus-host disease ( aGVHD) after liver transplantation.Methods This report included 8 patients treated with liver transplantation who were admitted to the Liver Transplantation Center of Beijing YouAn Hospital from April 2011 to August 2016. The key points in the diagnosis of aGVHD and the experience in the treatment of this disease were summarized. Results The key points in the diagnosis of aGVHD after liver transplantation were as follows: ( 1) aGVHD usually occur at two weeks to two months after liver transplantation; ( 2) fever, rash, diarrhea, and reduced whole blood cell count are typical clinical symptoms; ( 3) the percentage of donor T lymphocytes in peripheral blood is more than 10%; ( 4) there are typical histopathological manifestations. The experience in the treatment of aGVHD after liver transplantation were as follows: the overall steroid response rate is 20%-50%, and methylprednisolone ( 1. 5 mg·kg-1·d-1, one week) is recommended; high-dose glucocorticoids are not recommended, thus avoiding increased infection risk; high-dose immunosuppressant is one of the causes of aGVHD, and excessive application of immunosuppressant should be avoided in clinical practice; the prevention of respiratory infection and digestive tract infection was very important; enteral nutrition should be considered; second-line therapies such as siplizumab, antithymocyte globulin, and tumor necrosis factor-alpha inhibitor may play a certain therapeutic role; blood purification can be used to effectively eliminate cytokines and inflammatory mediators, which is helpful to the treatment of aGVHD. Conclusion The diagnostic criteria for aGVHD after liver transplantation are mainly based on time of onset, clinical symptoms, peripheral blood T lymphocyte chimerism rate, and histopathology. Hormone shock and reducing the dose of immunosuppressant may be effective treatments.

     

  • loading
  • [1] BURDICK JF, VOGELSANG GB, SMITH WJ, et al. Severe graft-versus-host disease in a liver-transplant recipient[J]. N Engl J Med, 1988, 318 (11) :689-691.
    [2] OFOSU A, ZABOLOTSKY A, RUFAIL M, et al. Graft-versushost disease, a rare complication after orthotopic liver transplantation[J]. Clin Case Rep, 2017, 6 (1) :238-239.
    [3] PERRI R, ASSI M, TALWALKAR J, et al. Graft vs. host disease after liver transplantation:A new approach is needed[J]. Liver Transpl, 2007, 13 (8) :1092-1099.
    [4] KOSUGI-KANAYA M, UEHA S, ABE J, et al. Long-lasting graft-derived donor T cells contribute to the pathogenesis of chronic graft-versus-host disease in mice[J]. Front Immunol, 2017, 8:1842.
    [5] SUN B, ZHAO C, XIA Y, et al. Late onset of severe graft-versus-host disease following liver transplantation[J]. Transpl Immunol, 2006, 16 (3-4) :250-253.
    [6] YILMAZ M, OZDEMIR F, AKBULUT S, et al. Chronic graftversus-host disease after liver transplantation:A case report[J].Transplantat Proc, 2012, 44 (6) :1751-1753.
    [7] TAYLOR AL, GIBBS P, SUDHINDRAN S, et al. Monitoring systemic donor lymphocyte macrochimerism to aid the diagnosis of graft-versus-host disease after liver transplantation[J]. Transplantation, 2004, 77 (3) :441-446.
    [8] ELFEKI MA, PUNGPAPONG S, GENCO PV, et al. Graft-versus-host disease after orthotopic liver transplantation:Multivariate analysis of risk factors[J]. Clin Transplant, 2015, 29 (12) :1063-1066.
    [9] KIM GY, SCHMELKIN LA, DAVIS MDP, et al. Dermatologic manifestations of solid organ transplantation-associated graft-versus-host disease:A systematic review[J]. J Am Acad Dermatol, 2018, 78 (6) :1097-1101.
    [10] KAKOTRICHI A, HIND J. Graft-versus-host disease in paediatric liver transplantation:A review of the literature[J]. S Afr Med J, 2017, 107 (10) :12133.
    [11] Mac MILLAN ML, WEISDORF DJ, WAGNER JE, et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease:Comparison of grading systems. Biology of blood and marrow transplantation[J]. Biol Blood Marrow Tr, 2002, 8 (7) :387-394.
    [12] XIE EB, XUAN FH, SUN XD, et al. An analysis of risk factors for early complications after liver transplantation[J]. J Clin Hepatol, 2018, 34 (6) :1282-1288. (in Chinese) 解恩博, 轩凤慧, 孙晓东, 等.肝移植术后早期并发症的危险因素分析[J].临床肝胆病杂志, 2018, 34 (6) :1282-1288.
    [13] DOMIATI-SAAD R, KLINTMALM GB, NETTO G, et al. Acute graft versus host disease after liver transplantation:Patterns of lymphocyte chimerism[J]. Am J Transplant, 2005, 5 (12) :2968-2973.
    [14] GEORGE B, PN N, DEVASIA AJ, et al. Post-transplant cyclophosphamide as sole graft-versus-host disease prophylaxis is feasible in patients undergoing peripheral blood stem cell transplantation for severe aplastic anemia using matched sibling donors[J]. Biol Blood Marrow Transplant, 2018, 24 (3) :494-500.
    [15] ZHAO Z, LEOW WQ. Concurrent hepatic tuberculosis and hepatic graft-versus-host disease in an allogeneic hematopoietic stem cell transplant recipient:A case report[J]. Transplant Proc, 2017, 49 (7) :1659-1662.
    [16] SCHRAGER JJ, VNENCAK-JONES CL, GRABER SE, et al.Use of short tandem repeats for DNA fingerprinting to rapidly diagnose graft-versus-host disease in solid organ transplant patients[J]. Transplantation, 2006, 81 (1) :21-25.
    [17] BILLINGHAM RE. The biology of graft-versus-host reactions[J]. Harvey Lect, 1966, 62:21-78.
    [18] MEVES A, EL-AZHARY RA, TALWALKAR JA, et al. Acute graft-versus-host disease after liver transplantation diagnosed by fluorescent in situ hybridization testing of skin biopsy specimens[J]. J Am Acad Dermatol, 2006, 55 (4) :642-646.
    [19] ANDRES AM, SANTAMARIA ML, RAMOS E, et al. Graft-vshost disease after small bowel transplantation in children[J]. J Pediatr Surg, 2010, 45 (2) :330-336; discussion 336.
    [20] FEITO-RODRIGUEZ M, de LUCAS-LAGUNA R, GOMEZFERNANDEZ C, et al. Cutaneous graft versus host disease in pediatric multivisceral transplantation[J]. Pediatr Dermatol, 2013, 30 (3) :335-341.
    [21] DEEG HJ. New strategies for prevention and treatment of graft-versus-host disease and for induction of graft-versus-leukemia effects[J].Int J Hematol, 2003, 77 (1) :15-21.
    [22] SALOMAO M, DORRITIE K, MAPARA MY, et al. Histopathology of graft-vs-host disease of gastrointestinal tract and liver:An update[J]. Am J Clin Pathol, 2016, 145 (5) :591-603.
    [23] CHEN GH, JIANG N. Research hotspots and considerations on immune tolerance in liver transplantation[J]. Organ Transpl, 2017, 8 (1) :1-4. (in Chinese) 陈规划, 姜楠.肝移植免疫耐受的研究热点和思考[J].器官移植, 2017, 8 (1) :1-4.
    [24] SMITH DM, AGURA E, NETTO G, et al. Liver transplant-associated graft-versus-host disease[J]. Transplantation, 2003, 75 (1) :118-126.
    [25] RASHIDI A, ROMEE R. Graft-versus-host disease after liver transplantation:The effect of recipient-donor age difference[J].Clin Transplant, 2016, 30 (3) :335-336.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (1754) PDF downloads(347) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return